Compare MasterCard Inc (MA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Tango Therapeutics Inc. — how do they compare? MasterCard Inc trades at $606.33 (market cap $529.81B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: MasterCard Inc is far larger — about 141.3× Tango Therapeutics Inc.'s market cap, and MasterCard Inc pays a 0.58% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 135 Days and Tango Therapeutics Inc. for 0 Days on average.
| MA | TNGX | |
|---|---|---|
Market Cap | $529.81B | $3.75B |
Volume | 3,710,695 | 9,619,106 |
Sector | Financials | Health |
52-Week High | $604.80 | $32.90 |
52-Week Low | $471.55 | $7.50 |
Typical Hold Time | 135 Days | 0 Days |
Enterprise Value | $542.84B | $2.77B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $604.80, up 1.63% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with 2025 revenue of $32.79B and net income of $14.97B, maintaining impressive profit margins above 45%. Recent earnings beats and institutional buying activity support the positive outlook, while the company continues expanding digital payment infrastructure globally.
Mastercard presents a compelling growth opportunity with 80% analyst buy ratings and a $668.67 consensus price target. Key risks include payment industry disruption from stablecoins and AI-driven competitors. The stock's premium valuation (P/E 33.27) requires sustained execution, but strong cash flow generation and strategic positioning support long-term upside potential.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
